Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
Disclosed are compounds of the formula: and compounds of the formula: wherein R 1 , R 2 , R 3 , R 4 , R 5 , u and v are as defined herein. Also disclosed are methods of treating pain (e.g., inflammatory pain, chronic pain, and neuropathic pain), methods of treating diabetes, and methods of inhibiting the absorption of cholesterol using compounds of formula I or IIA.
1. A compound of the formula:
or a pharmaceutically acceptable salt, solvate, prodrug or stereoisomer thereof, wherein:
R 1 is selected from the group consisting of: (1) aryl and (2) substituted aryl, and wherein:
the substituted aryl moieties are each independently substituted with one or more substituents independently selected from the group consisting of: (a) —(C═N—O-alkyl)CH 3 , (b) —NC(O)NH 2 , (c) —NC(O)NH(alkyl), (d) —NC(O)N(alkyl) 2 , (e) —SO 2 NH 2 , (f) —SO 2 NH(alkyl), (g) —SO 2 N(alkyl) 2 , (h) —CF 3 , (i) —OH, (j) -halo, (k) —CN, (l) -alkoxy, (m) —C(O)O-alkyl, (n) —S(O)alkyl, (o) —SO 2 -alkyl, (p) —P(O)(O-alkyl) 2 , and (q) alkyl;
R 2 is —C(O)NHQ A wherein Q A is substituted aryl, and wherein:
the substituted aryl is substituted with one or more substituents independently selected from the group consisting of: (a) —(C═N—O-alkyl)CH 3 , (b) —NC(O)NH 2 , (c) —NC(O)NH(alkyl), (d) —NC(O)N(alkyl) 2 , (e) —SO 2 NH 2 , (f) —SO 2 NH(alkyl), (g) —SO 2 N(alkyl) 2 , (h) —CF 3 , (i) —OH, (j) -halo, (k) —CN, (l) -alkoxy, (m) —C(O)O-alkyl, (n) —S(O)alkyl, (o) —SO 2 -alkyl, (p) —P(O)(O-alkyl) 2 , and (q) alkyl;
R 3 is selected from the group consisting of: (1) heteroaryl and (2) substituted heteroaryl; and wherein:
the substituted heteroaryl is substituted with one or more substituents independently selected from the group consisting of: (a) —(C═N—O-alkyl)CH 3 , (b) —NC(O)NH 2 , (c) —NC(O)NH(alkyl), (d) —NC(O)N(alkyl) 2 , (e) —SO 2 NH 2 , (f) —SO 2 NH(alkyl), (g) —SO 2 N(alkyl) 2 , (h) —CF 3 , (i) —OH, (j) -halo, (k) —CN, (l) -alkoxy, (m) —C(O)O-alkyl, (n) —S(O)alkyl, (o) —SO 2 -alkyl, (p) —P(O)(O-alkyl) 2 , and (q) alkyl; and
Each R 4 is —CH 2 —, and v is 2;
Each R 5 is —CH 2 —, and u is 2; and
wherein for compound of formula IIIC:
when R 1 is
then
R 2 is not:
wherein for compound of formula IIIC:
when R 1 is
then
R 2 is not:
wherein for compound of formula IIIC:
when R 1 is
then
R 2 is not:
wherein for compound of formula IIID:
when R 1 is
then
R 2 is not:
wherein for compound of formula IIID:
when R 1 is
then
R 2 is not:
2. The compound of claim 1 wherein R 3 is selected from the group consisting of:
wherein X 1 is selected from the group consisting of: Br, F, and Cl and —CN.
3. The compound of claim 1 wherein R 1 is selected from the group consisting of:
wherein each X 4 is independently selected from the group consisting of: Br, Cl, CN and —CF 3 .
4. A compound of the formula:
5. A pharmaceutical composition comprising:
at least one compound of claim 1 and a pharmaceutically acceptable carrier.
6. A compound of the formula:
or a pharmaceutically acceptable salt, solvate, prodrug or stereolsomer thereof, wherein:
R 1 is halo substituted phenyl;
R 2 is —C(O)NHQ A wherein Q A is halo substituted phenyl:
R 3 is pyridyl;
Each R 4 is —CH 2 —, and v is 2;
Each R 5 is —CH 2 —, and u is 2; and
wherein for compounds of formula IIIC:
when R 1 is
then
R 2 is not:
wherein for compounds of formula IIIC:
when R 1 is
then
R 2 is not:
wherein for compounds of formula IIID:
when R 1 is
then
R 2 is not: